三磷酸腺苷二钠氯化镁致严重心脏不良反应1例

1临床资料 患者,男,63岁,主因＂乏力、腹泻、尿黄、身黄半月＂于2017年2月10日急诊入院。该患者于2013年发现乙肝肝硬化,既往无＂心、脑、肺、肾＂等脏器慢性病史。入院查体：体温（T）36.4℃,心率（HR）84次/分,呼吸（RR）20次/分,血压（BP）136/62mmHg（1mmHg=0.133kPa）,精神差,计算力、记忆力、定向力轻度降低,双肺呼吸音正常,心脏各项检查正常。     

胃癌致肺栓塞1例

患者男,45岁,既往有＂腰椎间盘突出症＂病史8年,入院前20天开始行绝对卧床牵引治疗。因＂左侧胸痛4天,咯血气促2天＂于2009年7月6日收住我院呼吸内科。入院查体：体温38.2℃,脉搏110次/分,呼吸22次/分,血压130/80mmHg。左锁骨上可扪及一枚0.5cm×1.0cm大小淋巴结,质硬,无压痛,活动差。     

注射用骨肽致过敏性休克1例

病例：患者,女,21岁,因＂强直性脊柱炎＂入院,入院后查体：体温正常（36.4℃）、脉搏76次/分、呼吸20次/分、血压120/90mmHg（1mmHg=0.133kPa）。因治疗强直性脊柱炎于20：15给予患者注射用骨肽（商品名：西若非,黑龙江江世药业有限公司,     

注射用血凝酶致过敏性休克1例

病例：患者，女，18岁，因“全身反复浮肿近2周”于2007年7月12日入住我院肾内科。既往无其他病史及药物过敏史。入院查体：体温38．2℃，呼吸20次／分，心率100次／分，血压110／80mmHg（1mmHg=0．133KPa）。2007年7月10日外院尿常规显示：     

低分子肝素钙注射液致呼吸困难1例

病例：患者,男,78岁,因＂突发心前区闷痛3小时伴恶心、出汗＂来院就诊。入院心电图示：ST段呈弓背向上抬高,T波倒置,于2010年3月30日19：00以＂急性心肌梗死＂收住入院。患者既往无其他病史及过敏史。查体：体温36.8℃,脉搏64次/分,呼吸19次/分,     

注射用硫普罗宁致过敏性休克1例

病例：患者,男,56岁。因诊断为＂肝硬化（失代偿期）＂,于2009年7月13日入院治疗。入院检查：体温36.6℃,呼吸20次/分,血压120/70mmHg（1mmHg=0.133kPa）,心肺未见异常。查体：意识清楚,精神尚可,皮肤巩膜无黄染、     

注射用二丁酰环磷腺苷钙致过敏反应1例

1病例资料 患者,女,66岁,因＂胸闷、呼吸困难1周＂于2013年3月16日就诊于本院,入院诊断＂双肺炎症,冠心病,消化道溃疡＂。患者既往有冠心病、消化道溃疡病史,有青霉素过敏史。入院查体：体温：36.5℃,脉搏：78次min-1,呼吸：18次min-1,血压：120/75 mmHg（1 mmHg=133.2 Pa）;心脏听诊心律不规则。     

利奈唑胺致脓肿分枝杆菌感染患者双腓神经/足底神经损伤1例

摘要：＜正＞1 病例资料患者,女,27岁,身高159 cm, 体质量50 kg, 既往体健,否认药物食物过敏史,否认家族遗传病史。2019年7月4日因全身广泛皮肤溃疡入院。入院体检：T 36.7℃,P 110次/min, R 20次/min, BP 111/64 mmHg; 神志清楚,呼吸平稳,全身多处见直径1 cm类圆形溃疡,少许渗出液,无明显红肿、疼痛。     

注射用尤瑞克林致血压升高1例

病例：患者,男,85岁。因＂头晕伴失语＂入院就诊,4h前患者无明显诱因情况下出现头晕伴失语表现,无恶心呕吐,无气促,头痛症状;能听懂旁人言语,但自己不能开口完整表达意思。既往有2型糖尿病病史,高血压,冠心病,心肌梗死,支架植入术后,前列腺增生史,颈椎病病史。查体：体温（T）36.2℃,脉搏（P）64次/min,呼吸（R）20次/min,血压（BP）200/80mmHg。     

注射用血塞通（冻干）致过敏反应3例

1病例病例1：患者,女性,42岁。因＂头部眩晕1个月余＂于2012年4月12日入院。有高血压病史,无药物、食物过敏史。查体：体温（T）为36.4℃,呼吸（R）为76次/min,心率（P）为19次/min,血压（BP,收缩压/舒张压）140/100 mmHg（1 mmHg=0.133 kPa）。入院诊断：高血压病2级（高危组）。于入院当日给予注射用血塞通（冻干）注射液400 mg（黑龙江珍宝岛药业股份有限公司生产,规格：400 mg,批号：20110705）加入0.9%氯化钠250 ml中静脉滴注,30~40滴/min。约10 min后,     

Degraded and undegraded carrageenans and experimental gastric and duodenal ulceration

The prevention of histamine-induced gastric and duodenal ulceration in the guinea-pig has been examined using a series of undegraded and degraded carrageenans. Undegraded carrageenans were active at lower doses than degraded carrageenans. The high viscosity of the undegraded carrageenans in solution prevented their use in larger doses. Degradation of carrageenan without serious loss of sulphate, gives a product which allows the dose to be increased to an extent that its effect more than offsets the slight loss in activity caused by the degradation. No single feature of carrageenan structure can be related to anti-ulcer activity although degradation, and hence reduction of molecular size, generally reduces activity. Sulphate contents over 30% have little apparent effect on activity; κ-carrageenans were not consistently different in anti-ulcer activity from Λ-carrageenans. This contrasts with the antipeptic activity of carrageenans where κ-carrageenans are less active than their Λ-counter-parts. As with antipeptic activity, the degree of anti-ulcer activity is probably determined by a combination of structural features which includes molecular size and polyanionic properties.     

Affective and Anxiety Disorders and Alcohol and Drug Dependence:

Depression and anxiety frequently coexist in patients with substance use disorders. This clinically-oriented article examiens the relationship between these conditions and emphasizes data showing that substances of abuse can cause signs and symptoms of both depression and anxiety. These substance-related syndromes appear to have a different course and prognosis than uncomplicated, independent anxiety and major depressive disorders, and clinicians should consider the role of alcohol and other drugs in all patients presenting with these complaints. The authors will also outline an approach for diagnosing and managing patients with the combination of a substance use and depressive or anxiety disorder.     

Alcohol and Substance Use and Abuse in Women and Children

No abstract available for this article.     

Excretion and biotransformation of alfentanil and sufentanil in rats and dogs

The excretion and biotransformation of alfentanil (ALF) and sufentanil (SUF), two recent analogues of the synthetic opioid fentanyl, were studied after single iv administration of the tritium-labeled drugs in male rats and dogs. The drugs were almost completely metabolized in the two species, which resulted in a large number of metabolites. The excretion of the metabolites was rapid and exceeded 95% within 4 days, except for that of ALF metabolites in dogs (about 85%). For ALF, excretion of the radioactivity with the urine (73% in rats, about 76% in dogs) exceeded that with the feces. For SUF, excretion of the radioactivity with the urine amounted to 38 and 60% and that with the feces to 62 and 40%, in rats and dogs, respectively. Bile-cannulated rats excreted 68% with the bile within 24 hr after SUF dosing, and about 22% of this biliary radioactivity was subjected to enterohepatic circulation. After an ALF dose, the biliary excretion amounted to 24%, and the enterohepatic circulation was minimal. The main metabolic pathways of the two drugs were the oxidative N-dealkylation at the piperidine nitrogen and at the amide nitrogen, oxidative O-demethylation, aromatic hydroxylation, and the formation of ether glucuronides. N-[4-(Hydroxymethyl)-4-piperidinyl]-N-phenylpropanamide (M6) was the main metabolite of both ALF and SUF in rats. In dogs, the glucuronide of N-(4-hydroxyphenyl)propanamide (M5) was the main metabolite of ALF. After SUF dosing in dogs, N-[4-(methoxymethyl)-4-piperidinyl]-N-phenylpropanamide was more abundant than M5.